Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conjugated estrogen plus DDAVP versus DDAVP alone to reduce bleeding after kidney biopsy in kidney dysfunction
IRCT20240406061424N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of conjugated estrogens and desmopressin in chronic kidney disease (CKD), sponsored by Shiraz University of Medical Sciences. Started Nov 2022; status: completed.
02
Drugs
conjugated estrogensdesmopressin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on IRCT20240406061424N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240406061424N1.